{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12(10)"],"submitter":["Wang MM"],"pubmed_abstract":["<h4>Background</h4>Kirsten rat sarcoma viral oncogene homolog (<i>KRAS</i>) mutation seemingly suffered less effective therapeutic regimens in the absence of widely-accepted targeted drugs compared with other mutation types in non-small cell lung cancer (NSCLC). However, whether these non-selective therapy schedules for <i>KRAS</i> mutation matters is still under debate. Correspondingly, we aimed to compare the long term expectancy of indicated therapeutic regimes and further explore the optimal schemes of <i>KRAS</i> mutated NSCLC in the absence of targeted drugs in this retrospective study cohort.<h4>Methods</h4>We conducted a single-center retrospective analysis among 66 patients diagnosed with <i>KRAS</i>-mutant advanced NSCLC from November 2018 to December 2020. These enrolled cases w"],"journal":["Translational lung cancer research"],"pagination":["2030-2039"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10654440"],"repository":["biostudies-literature"],"pubmed_title":["Clinical outcomes of <i>KRAS</i>-mutant non-small cell lung cancer under untargeted therapeutic regimes in the real world: a retrospective observational study."],"pmcid":["PMC10654440"],"pubmed_authors":["Shan HL","Zhang Y","Wu S","Qu SY","Yang XM","Wang MM","Xu X","Song LQ","Zhang SY"],"additional_accession":[]},"is_claimable":false,"name":"Clinical outcomes of <i>KRAS</i>-mutant non-small cell lung cancer under untargeted therapeutic regimes in the real world: a retrospective observational study.","description":"<h4>Background</h4>Kirsten rat sarcoma viral oncogene homolog (<i>KRAS</i>) mutation seemingly suffered less effective therapeutic regimens in the absence of widely-accepted targeted drugs compared with other mutation types in non-small cell lung cancer (NSCLC). However, whether these non-selective therapy schedules for <i>KRAS</i> mutation matters is still under debate. Correspondingly, we aimed to compare the long term expectancy of indicated therapeutic regimes and further explore the optimal schemes of <i>KRAS</i> mutated NSCLC in the absence of targeted drugs in this retrospective study cohort.<h4>Methods</h4>We conducted a single-center retrospective analysis among 66 patients diagnosed with <i>KRAS</i>-mutant advanced NSCLC from November 2018 to December 2020. These enrolled cases w","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Oct","modification":"2026-06-03T09:46:25.308Z","creation":"2025-04-05T10:23:25.872Z"},"accession":"S-EPMC10654440","cross_references":{"pubmed":["38025817"],"doi":["10.21037/tlcr-23-449"]}}